{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T09:28:18Z","timestamp":1768901298419,"version":"3.49.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T00:00:00Z","timestamp":1630627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T00:00:00Z","timestamp":1630627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s10067-021-05893-3","type":"journal-article","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T21:11:47Z","timestamp":1630703507000},"page":"85-94","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Real-world data on change in work productivity, activity impairment, and quality of life in patients with psoriatic arthritis under anti-TNF therapy: a postmarketing, noninterventional, observational study"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3443-3117","authenticated-orcid":false,"given":"Omer","family":"Karadag","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ediz","family":"Dalkilic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gizem","family":"Ayan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orhan","family":"Kucuksahin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timucin","family":"Kasifoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neslihan","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suleyman Serdar","family":"Koca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veli","family":"Yazisiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pinar Talu","family":"Erten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet","family":"Sayarlioglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa Ender","family":"Terzioglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sukran","family":"Erten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umut","family":"Kalyoncu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,3]]},"reference":[{"issue":"10","key":"5893_CR1","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD (2017) Psoriatic arthritis. N Engl J Med 376(10):957\u2013970. https:\/\/doi.org\/10.1056\/NEJMra1505557","journal-title":"N Engl J Med"},{"issue":"1","key":"5893_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40744-018-0132-4","volume":"6","author":"LJ Tucker","year":"2019","unstructured":"Tucker LJ, Coates LC, Helliwell PS (2019) Assessing disease activity in psoriatic arthritis: a literature review. Rheumatol Ther 6(1):23\u201332. https:\/\/doi.org\/10.1007\/s40744-018-0132-4","journal-title":"Rheumatol Ther"},{"issue":"12","key":"5893_CR3","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1080\/1744666x.2020.1685382","volume":"15","author":"E Lubrano","year":"2019","unstructured":"Lubrano E, Scriffignano S, Perrotta FM (2019) TNF-alpha inhibitors for the six treatment targets of psoriatic arthritis. Expert Rev Clin Immunol 15(12):1303\u20131312. https:\/\/doi.org\/10.1080\/1744666x.2020.1685382","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"5893_CR4","doi-asserted-by":"publisher","first-page":"e000765","DOI":"10.1136\/rmdopen-2018-000765","volume":"4","author":"S Puk\u0161i\u0107","year":"2018","unstructured":"Puk\u0161i\u0107 S, Bolton-King P, Sexton J, Michelsen B, Kvien TK, Berner Hammer H (2018) DAPSA and ultrasound show different perspectives of psoriatic arthritis disease activity: results from a 12-month longitudinal observational study in patients starting treatment with biological disease-modifying antirheumatic drugs. RMD Open 4(2):e000765. https:\/\/doi.org\/10.1136\/rmdopen-2018-000765","journal-title":"RMD Open"},{"issue":"6","key":"5893_CR5","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s40257-018-0377-2","volume":"19","author":"J Bagel","year":"2018","unstructured":"Bagel J, Schwartzman S (2018) Enthesitis and dactylitis in psoriatic disease: a guide for dermatologists. Am J Clin Dermatol 19(6):839\u2013852. https:\/\/doi.org\/10.1007\/s40257-018-0377-2","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"5893_CR6","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1093\/rheumatology\/kew433","volume":"56","author":"W Tillett","year":"2017","unstructured":"Tillett W, Shaddick G, Jobling A, Askari A, Cooper A, Creamer P, Clunie G, Helliwell PS, James J, Kay L, Korendowych E, Lane S, Packham J, Shaban R, Thomas ML, Williamson L, McHugh N (2017) Effect of anti-TNF and conventional synthetic disease-modifying anti-rheumatic drug treatment on work disability and clinical outcome in a multicentre observational cohort study of psoriatic arthritis. Rheumatology (Oxford) 56(4):603\u2013612. https:\/\/doi.org\/10.1093\/rheumatology\/kew433","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"5893_CR7","doi-asserted-by":"publisher","first-page":"e000984","DOI":"10.1136\/rmdopen-2019-000984","volume":"5","author":"O Palsson","year":"2019","unstructured":"Palsson O, Love TJ, Gunnarsdottir AI, Gunnarsson PS, Runarsdottir EE, Krogh NS, Gudbjornsson B (2019) Patients with psoriatic arthritis who are not eligible for randomised controlled trials for TNF inhibitors have treatment response and drug survival similar to those who are eligible. RMD Open 5(2):e000984. https:\/\/doi.org\/10.1136\/rmdopen-2019-000984","journal-title":"RMD Open"},{"issue":"3","key":"5893_CR8","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/1346-8138.14745","volume":"46","author":"N Tsuruta","year":"2019","unstructured":"Tsuruta N, Narisawa Y, Imafuku S, Ito K, Yamaguchi K, Miyagi T, Takahashi K, Fukamatsu H, Morizane S, Koketsu H, Yamaguchi M, Hino R, Nakamura M, Ohyama B, Ohata C, Kuwashiro M, Sato T, Saito K, Kaneko S, Yonekura K, Hayashi H, Yanase T, Morimoto K, Sugita K, Yanagihara S, Kikuchi S, Mitoma C, Nakahara T, Furue M, Okazaki F (2019) Cross-sectional multicenter observational study of psoriatic arthritis in Japanese patients: relationship between skin and joint symptoms and results of treatment with tumor necrosis factor-\u03b1 inhibitors. J Dermatol 46(3):193\u2013198. https:\/\/doi.org\/10.1111\/1346-8138.14745","journal-title":"J Dermatol"},{"issue":"1","key":"5893_CR9","doi-asserted-by":"publisher","first-page":"e000659","DOI":"10.1136\/rmdopen-2018-000659","volume":"4","author":"D van der Heijde","year":"2018","unstructured":"van der Heijde D, Braun J, Rudwaleit M, Purcaru O, Kavanaugh AF (2018) Improvements in workplace and household productivity with certolizumab pegol treatment in axial spondyloarthritis: results to week 96 of a phase III study. RMD Open 4(1):e000659. https:\/\/doi.org\/10.1136\/rmdopen-2018-000659","journal-title":"RMD Open"},{"issue":"2","key":"5893_CR10","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1093\/rheumatology\/ker323","volume":"51","author":"CM Black","year":"2012","unstructured":"Black CM (2012) Sickness absence and musculoskeletal disorders. Rheumatology (Oxford) 51(2):204\u2013205. https:\/\/doi.org\/10.1093\/rheumatology\/ker323","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"5893_CR11","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1093\/rheumatology\/ker415","volume":"51","author":"P Short","year":"2012","unstructured":"Short P, Jones AC, Walker D, Kavanaugh A, Moots RJ (2012) Working at arthritis. Rheumatology (Oxford) 51(2):201\u2013203. https:\/\/doi.org\/10.1093\/rheumatology\/ker415","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"5893_CR12","doi-asserted-by":"publisher","first-page":"214","DOI":"10.3899\/jrheum.141077","volume":"43","author":"DE Beaton","year":"2016","unstructured":"Beaton DE, Dyer S, Boonen A, Verstappen SM, Escorpizo R, Lacaille DV, Bosworth A, Gignac MA, Leong A, Purcaru O, Leggett S, Hofstetter C, Peterson IF, Tang K, Fautrel B, Bombardier C, Tugwell PS (2016) OMERACT filter evidence supporting the measurement of at-work productivity loss as an outcome measure in rheumatology research. J Rheumatol 43(1):214\u2013222. https:\/\/doi.org\/10.3899\/jrheum.141077","journal-title":"J Rheumatol"},{"issue":"6","key":"5893_CR13","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M, Primdahl J, McGonagle DG, Aletaha D, Balanescu A, Balint PV, Bertheussen H, Boehncke WH, Burmester GR, Canete JD, Damjanov NS, Kragstrup TW, Kvien TK, Landew\u00e9 RBM, Lories RJU, Marzo-Ortega H, Poddubnyy D, Rodrigues Manica SA, Schett G, Veale DJ, Van den Bosch FE, van der Heijde D, Smolen JS (2020) EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 79(6):700\u2013712. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217159","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"5893_CR14","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.rdc.2009.10.001","volume":"35","author":"J Fransen","year":"2009","unstructured":"Fransen J, van Riel PL (2009) The Disease Activity Score and the EULAR response criteria. Rheum Dis Clin North Am 35(4):745-757 vii-viii. https:\/\/doi.org\/10.1016\/j.rdc.2009.10.001","journal-title":"Rheum Dis Clin North Am"},{"issue":"12","key":"5893_CR15","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1136\/annrheumdis-2018-213463","volume":"77","author":"B Michelsen","year":"2018","unstructured":"Michelsen B, Sexton J, Smolen JS, Aletaha D, Krogh NS, van der Heijde D, Kvien TK, Hetland ML (2018) Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for PSoriatic Arthritis (DAPSA) based on 28 joints? Ann Rheum Dis 77(12):1736\u20131741. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213463","journal-title":"Ann Rheum Dis"},{"key":"5893_CR16","unstructured":"Kalyoncu U BO, Oksuz MF, Kimyon G, Erden A, Yavuz S, Cetin G, Kucuksahin O, Kilic L, Omma A, Ozisler C, Solmaz D, Onat AM, Kisacik B, Ersozlu Bakirli D, Cinar M, Tufan A, Yildiz F, Mercan R, Kasifoglu T, Yilmazer B, Yilmaz S, Aksu K, Erten S, Sayarlioglu M, Dalkilic E, Akar S, Acikel C, Aydin Tufan M, Balkarli A, Kasapoglu-Gunal E, Senel S, Kobak S, Duruoz MT, Dogru A, Tarhan EF, Can M, Akyol L, Pehlevan S, Erbasan F, Arslan F, Kucuk A, Gonullu E, Kabasakal Y, Sahin M, Atakan N, Aydin SZ (2016) Dapsa-28 may be used instead of Dapsa-66\/68 in psoriatic arthritis [abstract]. Arthritis Rheumatol 68(10):3689\u20133690. https:\/\/acrabstracts.org\/abstract\/dapsa-28-may-be-used-instead-of-dapsa-6668-in-psoriatic-arthritis\/"},{"issue":"5","key":"5893_CR17","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/acr.23337","volume":"70","author":"MP Lee","year":"2018","unstructured":"Lee MP, Lii J, Jin Y, Desai RJ, Solomon DH, Merola JF, Kim SC (2018) Patterns of systemic treatment for psoriatic arthritis in the US: 2004\u20132015. Arthritis Care Res (Hoboken) 70(5):791\u2013796. https:\/\/doi.org\/10.1002\/acr.23337","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"5893_CR18","doi-asserted-by":"publisher","first-page":"350","DOI":"10.3899\/jrheum.150805","volume":"43","author":"FM Perrotta","year":"2016","unstructured":"Perrotta FM, Marchesoni A, Lubrano E (2016) Minimal disease activity and remission in psoriatic arthritis patients treated with anti-TNF-\u03b1 drugs. J Rheumatol 43(2):350\u2013355. https:\/\/doi.org\/10.3899\/jrheum.150805","journal-title":"J Rheumatol"},{"issue":"8","key":"5893_CR19","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54(8):2665\u20132673. https:\/\/doi.org\/10.1002\/art.21972","journal-title":"Arthritis Rheum"},{"issue":"5","key":"5893_CR20","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM (1993) The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 4(5):353\u2013365. https:\/\/doi.org\/10.2165\/00019053-199304050-00006","journal-title":"Pharmacoeconomics"},{"issue":"Suppl 2","key":"5893_CR21","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1136\/annrheumdis-2018-eular.2925","volume":"77","author":"I Klaudius","year":"2018","unstructured":"Klaudius I, Krueger K, Remstedt S, Thiele A (2018) SAT0187 Golimumab improves work productivity and activity impairment in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PSA): 1-year results from a non- interventional trial in Germany. Ann Rheum Dis 77(Suppl 2):954\u2013955. https:\/\/doi.org\/10.1136\/annrheumdis-2018-eular.2925","journal-title":"Ann Rheum Dis"},{"issue":"Supplement_1","key":"5893_CR22","doi-asserted-by":"publisher","first-page":"i21","DOI":"10.1093\/rheumatology\/keaa042","volume":"59","author":"P Mease","year":"2020","unstructured":"Mease P (2020) Enthesitis in psoriatic arthritis (Part 3): clinical assessment and management. Rheumatology (Oxford) 59(Supplement_1):i21\u2013i28. https:\/\/doi.org\/10.1093\/rheumatology\/keaa042","journal-title":"Rheumatology (Oxford)"},{"key":"5893_CR23","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3899\/jrheum.120254","volume":"89","author":"A Kavanaugh","year":"2012","unstructured":"Kavanaugh A, Mease P (2012) Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: longer-term outcomes including enthesitis and dactylitis with golimumab treatment in the Longterm Extension of a Randomized, Placebo-controlled Study (GO-REVEAL). J Rheumatol Suppl 89:90\u201393. https:\/\/doi.org\/10.3899\/jrheum.120254","journal-title":"J Rheumatol Suppl"},{"issue":"5","key":"5893_CR24","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1136\/annrheumdis-2015-207507","volume":"75","author":"MM Schoels","year":"2016","unstructured":"Schoels MM, Aletaha D, Alasti F, Smolen JS (2016) Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis 75(5):811\u2013818. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207507","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"5893_CR25","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1136\/ard.2004.032268","volume":"64","author":"C Antoni","year":"2005","unstructured":"Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, Zhou B, Dooley LT, Kavanaugh A (2005) Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 64(8):1150\u20131157. https:\/\/doi.org\/10.1136\/ard.2004.032268","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"5893_CR26","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1136\/ard.2008.092767","volume":"68","author":"PJ Mease","year":"2009","unstructured":"Mease PJ, Ory P, Sharp JT, Ritchlin CT, Van den Bosch F, Wellborne F, Birbara C, Thomson GT, Perdok RJ, Medich J, Wong RL, Gladman DD (2009) Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 68(5):702\u2013709. https:\/\/doi.org\/10.1136\/ard.2008.092767","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"5893_CR27","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.3899\/jrheum.100069","volume":"37","author":"DD Gladman","year":"2010","unstructured":"Gladman DD, Sampalis JS, Illouz O, Gu\u00e9rette B (2010) Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study. J Rheumatol 37(9):1898\u20131906. https:\/\/doi.org\/10.3899\/jrheum.100069","journal-title":"J Rheumatol"},{"issue":"10","key":"5893_CR28","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1002\/acr.22044","volume":"65","author":"A Kavanaugh","year":"2013","unstructured":"Kavanaugh A, McInnes IB, Krueger GG, Gladman D, Beutler A, Gathany T, Mack M, Tandon N, Han C, Mease P (2013) Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Care Res (Hoboken) 65(10):1666\u20131673. https:\/\/doi.org\/10.1002\/acr.22044","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"7","key":"5893_CR29","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1002\/acr.22256","volume":"66","author":"D Gladman","year":"2014","unstructured":"Gladman D, Fleischmann R, Coteur G, Woltering F, Mease PJ (2014) Effect of certolizumab pegol on multiple facets of psoriatic arthritis as reported by patients: 24-week patient-reported outcome results of a phase III, multicenter study. Arthritis Care Res (Hoboken) 66(7):1085\u20131092. https:\/\/doi.org\/10.1002\/acr.22256","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"5893_CR30","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/art.20967","volume":"52","author":"CE Antoni","year":"2005","unstructured":"Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J (2005) Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 52(4):1227\u20131236. https:\/\/doi.org\/10.1002\/art.20967","journal-title":"Arthritis Rheum"},{"issue":"4","key":"5893_CR31","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1136\/ard.2006.058339","volume":"66","author":"A Kavanaugh","year":"2007","unstructured":"Kavanaugh A, Krueger GG, Beutler A, Guzzo C, Zhou B, Dooley LT, Mease PJ, Gladman DD, de Vlam K, Geusens PP, Birbara C, Halter DG, Antoni C (2007) Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 66(4):498\u2013505. https:\/\/doi.org\/10.1136\/ard.2006.058339","journal-title":"Ann Rheum Dis"},{"issue":"9227","key":"5893_CR32","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/s0140-6736(00)02530-7","volume":"356","author":"PJ Mease","year":"2000","unstructured":"Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356(9227):385\u2013390. https:\/\/doi.org\/10.1016\/s0140-6736(00)02530-7","journal-title":"Lancet"},{"issue":"4","key":"5893_CR33","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1002\/art.24403","volume":"60","author":"A Kavanaugh","year":"2009","unstructured":"Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, Papp K, Zrubek J, Mudivarthy S, Mack M, Visvanathan S, Beutler A (2009) Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 60(4):976\u2013986. https:\/\/doi.org\/10.1002\/art.24403","journal-title":"Arthritis Rheum"},{"issue":"1","key":"5893_CR34","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","volume":"73","author":"PJ Mease","year":"2014","unstructured":"Mease PJ, Fleischmann R, Deodhar AA, Wollenhaupt J, Khraishi M, Kielar D, Woltering F, Stach C, Hoepken B, Arledge T, van der Heijde D (2014) Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 73(1):48\u201355. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203696","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"5893_CR35","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1080\/09546634.2017.1329509","volume":"29","author":"N Damjanov","year":"2018","unstructured":"Damjanov N, Karpati S, Kemeny L, Bakos N, Bobic B, Majdan M, Tlustochowicz W, Vitek P, Dokoupilova E, Aldinc E, Szumski A (2018) Efficacy and safety of etanercept in psoriasis and psoriatic arthritis in the PRESTA study: analysis in patients from Central and Eastern Europe. J Dermatolog Treat 29(1):8\u201312. https:\/\/doi.org\/10.1080\/09546634.2017.1329509","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"5893_CR36","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1093\/rheumatology\/kew375","volume":"56","author":"U Kalyoncu","year":"2017","unstructured":"Kalyoncu U, Bayindir \u00d6, Ferhat \u00d6ks\u00fcz M, Do\u011fru A, Kimyon G, Tarhan EF, Erden A, Yavuz \u015e, Can M, \u00c7etin GY, K\u0131l\u0131\u00e7 L, K\u00fc\u00e7\u00fck\u015fahin O, Omma A, Ozisler C, Solmaz D, Bozkirli ED, Akyol L, Pehlevan SM, Gunal EK, Arslan F, Y\u0131lmazer B, Atakan N, Ayd\u0131n SZ (2017) The Psoriatic Arthritis Registry of Turkey: results of a multicentre registry on 1081 patients. Rheumatology (Oxford) 56(2):279\u2013286. https:\/\/doi.org\/10.1093\/rheumatology\/kew375","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"5893_CR37","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1001\/jamadermatol.2013.133","volume":"149","author":"T Bhutani","year":"2013","unstructured":"Bhutani T, Wong JW, Bebo BF, Armstrong AW (2013) Access to health care in patients with psoriasis and psoriatic arthritis: data from National Psoriasis Foundation survey panels. JAMA Dermatol 149(6):717\u2013721. https:\/\/doi.org\/10.1001\/jamadermatol.2013.133","journal-title":"JAMA Dermatol"},{"issue":"4","key":"5893_CR38","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1093\/rheumatology\/keaa663","volume":"60","author":"G Ayan","year":"2021","unstructured":"Ayan G, Aydin SZ, Kimyon G, Ozisler C, Tinazzi I, Dogru A, Omma A, Kilic L, Y\u0131lmaz S, Kucuksahin O, G\u00f6n\u00fcll\u00fc E, Y\u0131ld\u0131z F, Can M, Balkarl\u0131 A, Solmaz D, Dalk\u0131l\u0131c E, Bayindir O, Y\u0131ld\u0131r\u0131m \u00c7etin G, Ergulu Esmen S, Ersozlu ED, Duruoz MT, Akyol L, Kucuk A, Bes C, C\u0131nar M, Erden A, Mercan R, Bakirci S, Kasifoglu T, Yaz\u0131s\u0131z V, Kalyoncu U (2021) PsART-ID inception cohort: clinical characteristics, treatment choices and outcomes of patients with psoriatic arthritis. Rheumatology (Oxford) 60(4):1755\u20131762. https:\/\/doi.org\/10.1093\/rheumatology\/keaa663","journal-title":"Rheumatology (Oxford)"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05893-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-021-05893-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05893-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T16:20:20Z","timestamp":1641313220000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-021-05893-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,3]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["5893"],"URL":"https:\/\/doi.org\/10.1007\/s10067-021-05893-3","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,3]]},"assertion":[{"value":"7 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Clinical Research Ethics Committee of Hacettepe University on October 31, 2013, with an approval number: 2013\/13\u201303 (KA-130083).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was received before enrolment from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"Omer Karadag: AbbVie (research grant, consulting fee), Pfizer (research grant, consulting fee), Roche (research grant, consulting fee), Novartis (research grant), Abdi \u0130brahim (consulting fee), Amgen (consulting fee), Farmanova (consulting fee), Janssen (consulting fee), Lilly (consulting fee), UCB (consulting fee). Ediz Dalkilic: AbbVie (speaker fee), MSD (speaker fee), Roche (speaker fee), Pfizer (speaker fee), UCB (speaker fee), Novartis (speaker fee). Gizem Ayan: None. Orhan Kucuksahin: None. Timucin Kasifoglu: AbbVie, Amgen, Roche, MSD, Novartis, Pfizer, and UCB (speaker and consulting fees). Neslihan Yilmaz: AbbVie (speaker fee), Pfizer (speaker fee), UCB (speaker fee), Roche (speaker fee), Janssen (speaker fee). Suleyman Serdar Koca: AbbVie (speaker fee), Pfizer (speaker fee), Roche (speaker fee), UCB (speaker fee), Novartis (speaker fee), Amgen (speaker fee), Pharmactive (speaker fee), MSD (speaker fee). Veli Yazisiz: AbbVie (consulting fee), Pfizer (consulting fee), UCB (consulting fee). Pinar Talu Erten: None. Mehmet Sayarlioglu: Genzyme (speaker fee), MSD (consulting fee), Novartis (research grant). Mehmet Ender Terzioglu: AbbVie, Pfizer, Novartis, Boehringer Ingelheim, Pharmactive, and UCB (speaker\/consulting fee and\/or research grant). Sukran Erten: Janssen (speaker fee), Roche (speaker fee), Novartis (speaker fee). Umut Kalyoncu: AbbVie, Pfizer (research grant, speaker, and consulting fee), Janssen (research grant, speaker fee), UCB, Novartis (speaker and consulting fee), Lilly (consulting fee).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}